论文部分内容阅读
目的:评价奥司他韦治疗妊娠期流感病毒感染的安全性。方法:计算机检索PubMed、The Cochrane library、EMbase、CNKI、WanFang data、维普、CBM数据库。按纽卡斯-渥太华量表(NOS量表)评价纳入研究质量后,对同质研究采用RevMan5.3进行Meta分析。结果:本研究共纳入6篇队列研究进行分析,奥司他韦暴露组共1 865例,非暴露组共138 414例。结果显示奥司他韦暴露组胎膜早破发生率与非暴露组比较,差异有统计学意义(P<0.05),奥司他韦暴露组胎膜早破发生率低于非暴露组;而在早产、先兆子痫及产时发热方面,2组比较差异均无统计学意义(P>0.05);在死胎或新生儿死亡发生率和阿普加评分<7分方面,奥司他韦暴露组与非暴露组比较,差异均无统计学意义(P>0.05);而在胎儿畸形和小样儿方面,2组比较差异均有统计学意义(P<0.05),奥司他韦暴露组胎儿畸形及小样儿发生率更低。结论:奥司他韦不增加妊娠流感患者早产、先兆子痫、产时发热、死胎或新生儿死亡等不良结局,并可减少胎膜早破、胎儿畸形和小样儿的发生风险。
OBJECTIVE: To evaluate the safety of oseltamivir in the treatment of influenza virus infection during pregnancy. Methods: We searched PubMed, The Cochrane library, EMbase, CNKI, WanFang data, VIP, CBM database. Following the inclusion of the study by the Newcastle-Ottawa Scale (NOS), Meta-analysis was performed on a homogeneous study using RevMan 5.3. RESULTS: Six cohort studies were included in this study. A total of 1 865 patients in the oseltamivir-exposed group and 138 414 non-exposed patients were enrolled. The results showed that the incidence of premature rupture of membranes in the oseltamivir exposure group was significantly higher than that in the non-exposed group (P <0.05), and the incidence of premature rupture of membranes was lower in the oseltamivir exposure group than in the non-exposed group There was no significant difference between the two groups in preterm labor, preeclampsia and labor fever (P> 0.05). In the stillbirth or neonatal mortality rate and Apgar score <7 points, oseltamivir exposure There were no significant differences between the two groups (P> 0.05), but there was no significant difference between the two groups (P> 0.05) Deformity and small sample incidence is lower. CONCLUSIONS: Oseltamivir does not increase the adverse outcomes of preterm labor, pre-eclampsia, labor-induced fever, stillbirth or neonatal death in pregnant women with pregnancy-induced influenza and can reduce the risk of premature rupture of membranes, fetal malformations and small samples.